Pharmetheus https://validator.w3.org/feed/docs/rss2.html Workshop: FREM in practical use: implementation and interpretation Events The Reference-Corrected Visual Predictive Check: A More Intuitive Diagnostic for Non-Linear Mixed Effects Models Paul Vrenken Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection New publication exploring drug-drug interactions (DDIs) and food effects for Bevurogant (BI 730357), a competitive antagonist of the retinoic acid-related orphan receptor γ (RORγ), investigated as an oral treatment for plaque psoriasis. New publication on reference-corrected visual predictive checks (rcVPCs) for non-linear mixed effects models. New publication: insights from the first Open Systems Pharmacology Community Conference Privacy Policy Pharmetheus at PAGE 2025 Pharmetheus at ASCPT 2025 Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference How can we help you? Marylore Chenel Symposium: MIDD in regulatory interactions – Practical takes on the Draft ICH M15 Guideline PBPK/PBBM consulting services Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption Pharmetheus appoints Regulatory Affairs Consultant Model Informed Drug Development (MIDD) consulting services Pharmacometrics consulting services Quantitative Systems Pharmacology (QSP) consulting services Home Benjamin Weber Mikael Haglund News Careers Attend the third annual Educational Pharmacometrics Summer Symposium in connection to PAGE 2025 Time to register for the Educational Pharmacometrics Summer Symposium 2025 Time to register for the Educational Pharmacometrics Summer Symposium 2024 Workshop: PBPK Modeling for First-in-Human & DDI with OSP Suite Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 Elodie Plan Chasing optimum First-in-Human dose – welcome to reality! Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report Lina Keutzer Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling “I’m not just creating a model, I’m trying to save lives” Workshop: Learn and apply TTE and RTTE modeling with a focus on NONMEM A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection Model-informed drug development of flucytosine sustained release formulation in the treatment of cryptococcal meningitis: A case study using PBPK modeling Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate Marie Wijk MIDD and pharmacology conferences we are attending in 2025 About us Speed advising for students Training Workshop Embedded Scientist Employee stories